Navigation Links
Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Date:9/26/2007

COLORADO SPRINGS, Colo., Sept. 26 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced it has enrolled the first patient in the PATENT trial utilizing the Company's TURBO elite(TM) laser catheters in combination with the recently FDA cleared TURBO-Booster(TM).

The PATENT trial is a prospective registry of 100 patients at up to 10 sites in Germany. The trial will assess patency as measured by duplex ultrasound at various intervals up to 12 months following the procedure. It will also assess safety as measured by adverse events up to 12 months following the procedure. In the initial procedure performed at the Leipzig Heart Center, four focal lesions were treated successfully with the TURBO-Booster and TURBO elite 2.0mm catheter in a 20cm long stented superficial femoral artery.

"The initial result from this Spectranetics device looks very promising, as the new features allow for ablation of more tissue in larger vessels," said Andrej Schmidt, M.D., of the University of Leipzig-Heart Center. "Instent restenosis in a superficial femoral artery represents one of the most challenging procedures in our practice. The current standard of care, such as repeat balloon angioplasty, does not have good results as these lesions tend to reoccur. We are very excited with the start of this study in Germany, and we look forward to examining the mid- and long-term results of this new therapy."

John G. Schulte, Spectranetics' President and Chief Executive Officer, commented, "We are very pleased to have begun this trial at one of Europe's most prestigious medical centers. We believe that instent restenosis in the superficial femoral artery may represent 25% to 35% of all above-the-knee proce
'/>"/>

SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 2014 Research and Markets  has ... Development Prospect of China Dialysis Market, 2014-2018" ... on the 2013 version, this update Report provides ... industry and the relevant effect in recent three ... segmentations. Moreover, it analyzes Chinese private-owned hemodialysis services. ...
(Date:10/17/2014)... 2014 Investor-Edge has initiated coverage ... ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ), and ... these five companies can be accessed at: http://investor-edge.com/register ... 16, 2014, ended on a mixed note as the ...
(Date:10/17/2014)... 17, 2014   InnFocus, Inc ., reported on results ... States for up to 3 years with the ... in Chicago . The Summit ... annual meeting of the American Academy of Ophthalmology . ... 150 glaucoma patients in 6 countries by early 2015. ...
Breaking Medicine Technology:Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
... Sept. 27, 2011 Thousands of jobs in Michigan ... if harmful policies – such as imposing new taxes ... by federal policymakers. From research to technical ... suppliers to child care services, the biopharmaceutical sector supports ...
... in Texas supported by the biopharmaceutical research sector would ... new taxes in the Medicare prescription drug program – ... to technical work, manufacturing to construction and other building ... sector supports a broad array of high-quality jobs. ...
Cached Medicine Technology:Research Demonstrates Possible Michigan Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Michigan Job Losses from Sectors Supported by Biopharmaceutical Companies 3Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies 3
(Date:10/20/2014)... San Diego, CA (PRWEB) October 20, 2014 ... regarding all the latest information from the FDA on ... consumers on October 10 not to purchase or use Sit ... Phenolphthalein. Sit and Slim II is promoted as weight loss ... , Sibutramine, removed from the market in 2010 for safety ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
(Date:10/19/2014)... 20, 2014 SweetDressy.com, a professional company ... its promotion for long evening dresses . All ... special offer; the current discount is up to 66 ... industry pioneers in the fashion field. Its dress specialists ... dwelling in various parts of the world. All the ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... better understand where to focus efforts to ... CAMBRIDGE, MA, May 28 /PRNewswire/ - rL ... software that helps organizations manage,infection control issues, patient ... claims and quality issues,announced today that Caritas Christi ...
... N.C., May 28 Take advantage of quick ... attend the 10th Annual Human,Resources Conference: Leadership Development ... full conference agenda at, http://www3.best-in-class.com/gr163.htm ), sponsored ... 2008, at The Ritz-Carlton,Hotel, Sarasota, Fla., Registration ...
... TV Leader Guthy-Renker Attracts yet Another Celebrity for ... America,s Best-Selling Acne ... announced,today that Ryan Sheckler, famed skateboarder and television star, ... acne treatment,Proactiv Solution. Known for its wide range of ...
... Million Home-Device Market With First-to-Market ... Technology, Strong Branding, ... series of corporate milestones in anticipation of FDA clearance,for CLARO, ... the appointment of a senior marketing,executive, expansion of the Board ...
... 28 Shamir Optical,Industry Ltd. (Nasdaq: SHMR ) ... the progressive ophthalmic lens market, today,announced unaudited financial results ... the quarter ended March 31, 2008, revenues increased 29.5% ... the same period of 2007.,Gross profit for the quarter ...
... LOS ANGELES, May 28 5-year-old Noor came to,the ... Division,s 1st,Battalion, 30th Infantry Regiment, 2nd Brigade Combat Team ... that resulted,in the death of the little girl,s uncle. ... battalion surgeon, concluded that Noor is blind,due to a ...
Cached Medicine News:Health News:Caritas Christi Standardizes on rL Solutions to Help Deliver Best in Class Healthcare Quality 2Health News:Registration Ends This Week: Fortune 500 Networking & Best Practice Sharing Conference in Florida 2Health News:Professional Skateboarder Ryan Sheckler to Become the Newest Face of Proactiv Solution 2Health News:Professional Skateboarder Ryan Sheckler to Become the Newest Face of Proactiv Solution 3Health News:CLRS Technology Accelerates Infrastructure Growth Anticipating FDA Clearance for At-Home IPL Acne Device 2Health News:CLRS Technology Accelerates Infrastructure Growth Anticipating FDA Clearance for At-Home IPL Acne Device 3Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 2Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 3Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 4Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 5Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 6Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 7Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 8Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 9Health News:Photos: Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5-Year-Old Blind Iraqi Girl, Whose Father Stands Beside US Combat Team Against Al Qaeda, to the US for a Groundbreaking Artificial Corneal Transplant Surger 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: